Products—Current and future portfolio

We research and develop new products through employee initiatives and strategic alliances—to us, it’s the key to both anticipating and serving the changing needs of customers and patients.

Currently marketed products

Full prescribing information

Healthcare professional website

Patient website

LIVALO is a registered trademark of the Kowa group of companies.

When the going gets tough, Kowa gets going: The LIVALO story

We started our journey with LIVALO in 2010. We really had our work cut out for us. At that time, LIVALO was the seventh statin to the US market. Moreover, the market was dominated by legendary brands like Lipitor^® (atorvastatin calcium), Crestor^® (rosuvastatin), and Zocor^® (simvastatin).

Despite all of these challenges, Kowa buckled down and did what we do best—work. We implemented a new sales training regime and went into the field. After a lot of hard work by a lot of talented people, sales grew substantially.

Today, LIVALO is still on the market and selling well with millions of patients receiving a LIVALO prescription.

Lipitor is a registered trademark of Pfizer, Inc.
Crestor is a registered trademark of the AstraZeneca group of companies.
Zocor is a registered trademark of Merck & Co., Inc.

Product pipeline

Kowa’s Research & Development activities are carried out at the company’s laboratories in Tokyo and Fuji. The focus is on lifestyle-related diseases, immune disorders, allergy, dermatology, and ophthalmology.

Kowa Research Institute is responsible for the US development of Kowa’s new drug candidates. Kowa has several drugs currently in Phase 1 or later clinical development for conditions such as dyslipidemia, type 2 diabetes mellitus, and cancer.

Please click here for an overview of Kowa’s drug candidates in Phase 1 or later clinical development.